A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Allergan

Status: Completed

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Treatments: Drug: Bimatoprost 0.01%

Study type: Observational

Funder types: Industry

Identifiers

NCT01814761

GMA-AP-EYE-AGN-001

Details and patient eligibility

About

This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

Enrollment: 312 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary open-angle glaucoma or ocular hypertension
• Determined by the treating physician to require treatment with bimatoprost 0.01%.

Exclusion criteria

• Previous use of Lumigan® 0.01%

Trial design

312 participants in 2 patient groups

Pts with POAG or OH (Previously Treatment Naive)

Description:

Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

Treatment:

Drug: Bimatoprost 0.01%

Pts with POAG or OH (Switched Monotherapy)

Description:

Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

Treatment:

Drug: Bimatoprost 0.01%